Good morning :)
Place Order
Add to Watchlist

Nath Bio-Genes (I) Ltd

NATHBIOGEN

Nath Bio-Genes (I) Ltd

NATHBIOGEN
Consumer StaplesAgro Products
SmallcapWith a market cap of ₹421 cr, stock is ranked 1,914
High RiskStock is 3.21x as volatile as Nifty
221.120.30% (-0.66)
221.120.30% (-0.66)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Consumer StaplesAgro Products
SmallcapWith a market cap of ₹421 cr, stock is ranked 1,914
High RiskStock is 3.21x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

Avg

Can be considered moderately valued vs the market

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Consumer StaplesAgro Products
SmallcapWith a market cap of ₹421 cr, stock is ranked 1,914
High RiskStock is 3.21x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
10.180.690.90%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
56.0811.131.29%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Nath Bio-Genes (India) is engaged in hybrid seed business and production, processing and marketing of hybrid and genetically modified (GM) seeds

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.62%, vs industry avg of 6.32%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.98%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 0.62%, vs industry avg of 4.87%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue162.80170.39192.59233.20281.71309.23280.21301.91336.70345.31
Raw Materialssubtract4.361.972.715.497.358.963.565.3112.26290.02
Power & Fuel Costsubtract0.520.580.730.951.021.231.071.391.13
Employee Costsubtract13.6313.7411.8916.4318.7423.6924.7823.3227.58
Selling & Administrative Expensessubtract68.4752.0948.2360.8675.6774.8589.99112.25139.47
Operating & Other expensessubtract50.4972.4987.63103.83122.32132.07210.53110.11102.23
Depreciation/Amortizationsubtract3.903.030.951.451.452.823.083.013.263.33
Interest & Other Itemssubtract6.359.7310.395.336.658.8710.6410.369.208.59
Taxes & Other Itemssubtract0.910.470.630.44-1.981.093.951.151.951.97
EPS8.8510.1816.8120.2226.5729.28-35.4618.4220.8521.78
DPS0.000.000.000.000.002.002.002.002.002.00
Payout ratio0.000.000.000.000.000.070.110.100.09

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Jun 24PDF
FY 2022

Annual report

PDF

Investor Presentation

May 30PDF
Feb 14PDF
Nov 1PDF
Aug 10PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 22PDF
Feb 14PDF
Oct 20PDF
Aug 13PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
 

Peers & Comparison

Comparing 3 stocks from 
Consumer StaplesAgro Products

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Nath Bio-Genes (I) Ltd10.640.690.90%
Godrej Agrovet Ltd42.365.221.26%
Gujarat Ambuja Exports Ltd18.932.360.25%
Sanstar Ltd34.949.19

Price Comparison

Compare NATHBIOGEN with any stock or ETF
Compare NATHBIOGEN with any stock or ETF
NATHBIOGEN
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 2.05%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding45.60%4.37%0.00%0.22%49.81%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun0.13%0.08%0.22%0.32%0.27%0.22%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Nath Bio-Genes (I) Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Aditya Birla Sun Life Pure Value Fund - Growth - Direct Plan

Growth
4.4591%0.30%0.01%38/86 (-3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 9, 2024

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Aug 9, 2024

Cash Dividend

Ex DateEx DateJul 4, 2023

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jul 4, 2023

Cash Dividend

Ex DateEx DateJun 23, 2022

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jun 23, 2022

Cash Dividend

Ex DateEx DateAug 18, 2021

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Aug 18, 2021

News & Opinions
Earnings
Nath Bio-Genes (India) consolidated net profit declines 0.24% in the June 2024 quarter

Net profit of Nath Bio-Genes (India) declined 0.24% to Rs 33.35 crore in the quarter ended June 2024 as against Rs 33.43 crore during the previous quarter ended June 2023. Sales rose 3.66% to Rs 243.88 crore in the quarter ended June 2024 as against Rs 235.28 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales243.88235.28 4 OPM %14.9815.74 - PBDT34.4334.38 0 PBT33.6033.62 0 NP33.3533.43 0 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Nath Bio-Genes (India) announces board meeting date

Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 7 August 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live

Dividend paying stocks 2022: 5 stocks to turn ex-dividend tomorrow

2 years agoLivemint

Nath Bio-Genes (India) standalone net profit declines 59.14% in the September 2021 quarter

2 years agoBusiness Standard

Minda Corporation Ltd leads gainers in ‘A’ group

2 years agoBusiness Standard

Top stocks in focus: Aarey Drugs & Pharmaceuticals, Fortis Malar Hospitals, Nath Bio-Genes, Pricol, Gujarat Alkalies and Chemicals

3 years agoIndia Infoline

Nath Bio-Genes (India) standalone net profit rises 8.85% in the June 2021 quarter

3 years agoBusiness Standard

Nath Bio-Genes Standalone June 2021 Net Sales At Rs 214.64 Crore, Up 11.07% Y-o-Y

3 years agoMoneycontrol

Take Solutions Ltd leads losers in ‘A’ group

3 years agoBusiness Standard

Nath Bio-Genes (India) standalone net profit declines 6.42% in the March 2021 quarter

3 years agoBusiness Standard